| ■ 英語タイトル：Global Bleeding Disorders Treatment Market Size study & Forecast, by Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), by Drug Class (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others) and Regional Analysis, 2022-2029
|
 | ■ 発行会社/調査会社：Bizwit Research & Consulting
■ 商品コード：BZW23MR034
■ 発行日：2023年2月27日
■ 調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
■ 産業分野：医療
■ ページ数：約200
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後3営業日）
|
■ 販売価格オプション
（消費税別）
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Bizwit Research & Consulting社の概要及び新刊レポートはこちらでご確認いただけます。
| ★グローバルリサーチ資料[出血性疾患治療のグローバル市場（2022年-2029年）：血友病A、血友病B、フォン・ヴィレブランド病、その他]についてメールでお問い合わせはこちら
|
*** レポート概要（サマリー）***Bizwit Research社の市場調査レポートは、2021年にXX億ドルであった世界の出血性疾患治療市場規模が、2022年から2029年の間にXX%成長すると推測しています。本書では、出血性疾患治療の世界市場を広く調査し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、種類別（血友病A、血友病B、フォン・ヴィレブランド病、その他）分析、薬剤種類別（血漿由来凝固因子濃縮製剤、組換え凝固因子濃縮製剤、デスモプレシン、抗線溶薬、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争状況、調査プロセスなどについて以下の構成でまとめています。なお、参入企業情報として、Novo Nordisk A/S、Baxter International Inc.、Alnylam Pharmaceuticals, Inc.、Pfizer, Inc.、Xenetic Biosciences, Inc.、Bristol-Myers Squibb Company、Sanofi S.A.、Amgen, Inc.、Janssen Global Services, LLC.、Bioverativ, Inc.などが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の出血性疾患治療市場規模：種類別
- 血友病Aの市場規模
- 血友病Bの市場規模
- フォン・ヴィレブランド病の市場規模
- その他種類の市場規模
・世界の出血性疾患治療市場規模：薬剤種類別
- 血漿由来凝固因子濃縮製剤の市場規模
- 組換え凝固因子濃縮製剤の市場規模
- デスモプレシンの市場規模
- 抗線溶薬の市場規模
- その他薬剤種類の市場規模
・世界の出血性疾患治療市場規模：地域別
- 北米の出血性疾患治療市場規模
- ヨーロッパの出血性疾患治療市場規模
- アジア太平洋の出血性疾患治療市場規模
- 中南米の出血性疾患治療市場規模
- その他地域の出血性疾患治療市場規模
・競争状況
・調査プロセス |
Global Bleeding Disorders Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bleeding Disorders are a group of disorders that affect body’s ability to form proper blood clot. Its symptoms include excessive bleeding after injury, surgery, mensuration among others. Moreover, this improper clotting is mainly caused by defects in blood components such as platelets and/or clotting proteins. Bleeding disorders are generally caused by low red blood cell count, a vitamin K deficiency and side effects from certain medications. The increasing prevalence of Hemophilia and growing government initiatives for disease awareness are key factors driving the market growth.
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. Its prevalence has progressively increased during the last few decades. According to the Centers for Disease Prevention and Control (CDC) estimates – the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 U.S. males for hemophilia A and 3.7 cases per 100,000 U.S. males for hemophilia B. Additionally, around 30,000 and 33,000 males are living with hemophilia in the country. Moreover, as per The Hemophilia Society – in UK, one in 2,000 men, women and children have a diagnosed bleeding disorder. Additionally, most common is von Willebrand disorder (VWD), which affects around 7,071 women and 4,081 men in the country. Also, rising healthcare investment in developing regions and growing digital transformation in health care sector would create lucrative growth prospectus for the market over the forecast period. However, the high cost of Bleeding Disorders Treatment and dearth of skilled professionals stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Bleeding Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing awareness towards bleeding disorders in the region.
Major market player included in this report are:
Novo Nordisk A/S
Baxter International Inc.
Alnylam Pharmaceuticals, Inc.
Pfizer, Inc.
Xenetic Biosciences, Inc.
Bristol-Myers Squibb Company
Sanofi S.A.
Amgen, Inc.
Janssen Global Services, LLC.
Bioverativ, Inc.
Recent Developments in the Market:
In November 2022, CSL Behring LLC’s Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have experienced recent or past life-threatening haemorrhage, or have experienced repeated, severe spontaneous bleeding episodes.
Global Bleeding Disorders Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Drug Class, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Drug Class
Plasma-derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Bleeding Disorders Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Bleeding Disorders Treatment Market, by Type, 2019-2029 (USD Billion)
1.2.3. Bleeding Disorders Treatment Market, by Drug Class, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Bleeding Disorders Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Bleeding Disorders Treatment Market Dynamics
3.1. Bleeding Disorders Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of Hemophilia
3.1.1.2. Growing government initiatives for disease awareness
3.1.2. Market Challenges
3.1.2.1. High cost of Bleeding Disorders Treatment
3.1.2.2. Dearth of skilled professionals
3.1.3. Market Opportunities
3.1.3.1. Rising healthcare investment in developing regions
3.1.3.2. Growing digital transformation in health care sector
Chapter 4. Global Bleeding Disorders Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Bleeding Disorders Treatment Market, by Type
6.1. Market Snapshot
6.2. Global Bleeding Disorders Treatment Market by Type, Performance – Potential Analysis
6.3. Global Bleeding Disorders Treatment Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Bleeding Disorders Treatment Market, Sub Segment Analysis
6.4.1. Hemophilia A
6.4.2. Hemophilia B
6.4.3. Von Willebrand Disease
6.4.4. Others
Chapter 7. Global Bleeding Disorders Treatment Market, by Drug Class
7.1. Market Snapshot
7.2. Global Bleeding Disorders Treatment Market by Drug Class, Performance – Potential Analysis
7.3. Global Bleeding Disorders Treatment Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
7.4. Bleeding Disorders Treatment Market, Sub Segment Analysis
7.4.1. Plasma-derived Coagulation Factor Concentrates
7.4.2. Recombinant Coagulation Factor Concentrates
7.4.3. Desmopressin
7.4.4. Antifibrinolytics
7.4.5. Fibrin Sealants
7.4.6. Others
Chapter 8. Global Bleeding Disorders Treatment Market, Regional Analysis
8.1. Bleeding Disorders Treatment Market, Regional Market Snapshot
8.2. North America Bleeding Disorders Treatment Market
8.2.1. U.S. Bleeding Disorders Treatment Market
8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Drug Class breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Bleeding Disorders Treatment Market
8.3. Europe Bleeding Disorders Treatment Market Snapshot
8.3.1. U.K. Bleeding Disorders Treatment Market
8.3.2. Germany Bleeding Disorders Treatment Market
8.3.3. France Bleeding Disorders Treatment Market
8.3.4. Spain Bleeding Disorders Treatment Market
8.3.5. Italy Bleeding Disorders Treatment Market
8.3.6. Rest of Europe Bleeding Disorders Treatment Market
8.4. Asia-Pacific Bleeding Disorders Treatment Market Snapshot
8.4.1. China Bleeding Disorders Treatment Market
8.4.2. India Bleeding Disorders Treatment Market
8.4.3. Japan Bleeding Disorders Treatment Market
8.4.4. Australia Bleeding Disorders Treatment Market
8.4.5. South Korea Bleeding Disorders Treatment Market
8.4.6. Rest of Asia Pacific Bleeding Disorders Treatment Market
8.5. Latin America Bleeding Disorders Treatment Market Snapshot
8.5.1. Brazil Bleeding Disorders Treatment Market
8.5.2. Mexico Bleeding Disorders Treatment Market
8.5.3. Rest of Latin America Bleeding Disorders Treatment Market
8.6. Rest of The World Bleeding Disorders Treatment Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Novo Nordisk A/S
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Baxter International Inc.
9.2.3. Alnylam Pharmaceuticals, Inc.
9.2.4. Pfizer, Inc.
9.2.5. Xenetic Biosciences, Inc.
9.2.6. Bristol-Myers Squibb Company
9.2.7. Sanofi S.A.
9.2.8. Amgen, Inc.
9.2.9. Janssen Global Services, LLC.
9.2.10. Bioverativ, Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
*** 免責事項 ***https://www.globalresearch.co.jp/disclaimer/
